WINNIPEG, Manitoba, June 21, 2018 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (OTCQB:KNBIF), (the “Corporation” or “Kane Biotech”) is pleased to announce that it will be attending SuperZoo, North America’s leading pet retail trade exposition and conference, taking place June 26-28, 2018 at the Mandalay Bay Convention Center in Las Vegas, NV. Mark Ahrens-Townsend, Chief Executive Officer of Kane Biotech, along with key members of the Kane Biotech team will be attending the conference to showcase Kane Biotech’s bluestem™ brand of premium pet oral care products and to highlight their new bluestem™ skin care shampoo for dogs and cats.

Rendering of Kane's Exhibit at SuperZoo

Kane Biotech’s bluestem™ exhibit will be at booth #417 with a display promoting the benefits of their proprietary coactiv+™ oral care technology – a unique formulation scientifically developed to break down biofilm where harmful bacteria multiply. “I personally invite all buyers attending SuperZoo to visit our booth and learn more about our innovative, clinically proven, safe and effective bluestem products”, commented Mr. Ahrens-Townsend. “We are currently sold in 900 pet specialty stores in Canada and the U.S. and we’re eager to build on those numbers at SuperZoo this year.” Bluestem oral care is available in a water additive, toothpaste, and oral spray.

The Company introduced its companion pet oral care products in Canada under the StrixNB and bluestem brands and received notification under Health Canada’s Low Risk Veterinary Health Products (known as LRVHP) program, which Health Canada recently replaced with the Veterinary Health Products (VHP) - Notification Program. Approvals under these programs are in place for an oral care liquid water additive, a water additive powder formulation, an oral spray formulation and a toothpaste.

Kane Biotech will also be demonstrating its new bluestem™ skin care shampoo, scheduled for commercialization this year. The shampoo is scientifically formulated to support the natural defenses of the skin to improve the skin condition and coat of dogs and cats (and horses too). The new formulation soothes and moisturizes skin irritations, itching, redness and dryness and helps cleanse minor wounds. “We encourage pet retailers to stop by the booth and ask for a free sample bottle. We’d love for you to try it on your pet and provide us with feedback”, added Mr. Ahrens-Townsend.

Biofilms are estimated to be involved in 80% of animal and human bacterial infections, including tooth decay, skin disorders, hospital acquired infections (HAIs), chronic wounds, and foodborne disease outbreaks. Kane Biotech has several formulations in development for both animal and human applications, based on its patented and patent-pending antibiofilm technologies.

Investors attending the conference who would like to meet with Kane Biotech management are encouraged to contact Kane Biotech Investor Relations at tpatel@edisongroup.com.

About SuperZoo
SuperZoo is the most-attended pet industry trade show in North America, established by World Pet Association in 1950 as an annual gathering place for the entire industry to connect, learn and do business. Ever since, the show has continued to grow—and it now boasts more buyers and education hours than any other industry event on the continent. With its rich education offerings, easy-to-shop show floor and energizing, fun-filled atmosphere, SuperZoo has earned its reputation as North America’s premier pet retail event—and the industry’s most productive and vibrant trade show of the year.

About Kane Biotech Inc.
Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The Corporation has a portfolio of biotechnologies, intellectual property (75 patents and patents pending, trade secrets and trademarks) and products developed by the Corporation’s own biofilm research expertise and acquired from leading research institutions. StrixNB™, DispersinB®, Aledex®, bluestem™, AloSera™, coactiv+™ and Kane™ are trademarks of Kane Biotech Inc.  The Corporation is listed on the TSX Venture Exchange under the symbol "KNE" and on the OTCQB Venture Market under the symbol “KNBIF.”

For more information, please visit www.kanebiotech.com or contact:

Mark Ahrens-Townsend
President & CEO
Kane Biotech Inc.
+1 (204) 477-7592
ir@kanebiotech.com

Tirth Patel
Vice President - Investor Relations
Edison Advisors
+1 (646) 653-7035
tpatel@edisongroup.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/d5db54f0-11bb-4d5c-9cd6-eaf25d2a4dfd

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.